Berlin, Germany

Christoph Geserick


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2004

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Christoph Geserick: Innovator in Birth Control and Alzheimer's Treatment

Introduction

Christoph Geserick is a notable inventor based in Berlin, Germany. He has made significant contributions to the fields of reproductive health and neurodegenerative diseases. His innovative work focuses on the human PEM polypeptide, which plays a crucial role in sperm maturation and Alzheimer's disease.

Latest Patents

Geserick holds a patent for his invention titled "Human PEM as a target for birth control and treatment of Alzheimer's disease." This invention relates to the human PEM polypeptide and its potential applications in male birth control and the treatment of Alzheimer's disease. The patent outlines the use of PEM as a target in male contraception and for diagnosing and treating male infertility and Alzheimer's disease. It also includes a selection process for PEM antagonists and the production of binding molecules that specifically detect PEM. Additionally, the invention encompasses genes regulated by the PEM gene.

Career Highlights

Christoph Geserick is associated with Schering Aktiengesellschaft, a prominent company in the pharmaceutical industry. His work has garnered attention for its potential impact on both reproductive health and neurodegenerative disease treatment.

Collaborations

Geserick has collaborated with notable colleagues, including Bertram Weiss and Bernard Jacques Haendler. Their combined expertise has contributed to the advancement of research in their respective fields.

Conclusion

Christoph Geserick's innovative work in the realm of human PEM polypeptide has the potential to revolutionize male birth control and Alzheimer's disease treatment. His contributions reflect the importance of research and innovation in addressing significant health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…